Source comparison
Best Peptides for Muscle Soreness Recovery DOMS: Research Compound Comparison
BPC-157 VEGF upregulation, angiogenesis, anti-inflammatory cytokine modulation 200–500 mcg daily, subcutaneous Inflammatory phase (0–48 hours) Animal models + observational human data Strongest mechanistic case for acute DOMS intervention; limited human RCT da
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation, angiogenesis, anti-inflammatory cytokine modulation
- 200–500 mcg daily, subcutaneous
- Inflammatory phase (0–48 hours)
- Animal models + observational human data
- Strongest mechanistic case for acute DOMS intervention; limited human RCT data
- TB-500 (Thymosin Beta-4)
- Actin binding, satellite cell migration, reduced fibrosis
- 2–5 mg weekly, split doses
- Regenerative phase (48–96 hours)
- Tendon healing studies + muscle injury animal models
- Better suited for repeated microtrauma over acute single-session DOMS
- Ipamorelin
- GH secretagogue, IGF-1 upregulation, mTOR activation
- 200–300 mcg nightly
- Systemic recovery over weeks
- Clinical endocrinology studies
- Indirect benefit; cumulative rather than immediate
- CJC-1295/Ipamorelin Blend
- Extended GH pulse + secretagogue synergy
- 100 mcg CJC + 200 mcg Ipamorelin nightly
- Systemic recovery + protein synthesis
- Combination therapy observational data
- Higher total GH exposure than Ipamorelin alone; desensitization risk lower than Hexarelin
- Hexarelin
- Potent GH secretagogue, ghrelin receptor agonist
- 100–200 mcg daily (cycle 4–6 weeks)
- Systemic recovery + appetite modulation
- Small human trials + endocrine studies
- Strongest GH response; requires cycling to prevent receptor downregulation